J
Jaap Verweij
Researcher at Erasmus University Medical Center
Publications - 122
Citations - 8664
Jaap Verweij is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Cancer & Pharmacokinetics. The author has an hindex of 48, co-authored 122 publications receiving 7983 citations. Previous affiliations of Jaap Verweij include Uppsala University & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
Maria Debiec-Rychter,H. Dumez,Ian Judson,Bartosz Wasag,Jaap Verweij,M. Brown,Sasa Dimitrijevic,Raphael Sciot,Michel Stul,H. Vranck,Michelle Scurr,Anne Hagemeijer,M. van Glabbeke,A.T. Van Oosterom +13 more
TL;DR: Findings indicate that the mutational status of the c-KIT/PDGFRA oncoproteins could be useful to predict the clinical response of patients imatinib therapy.
Journal ArticleDOI
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
Penella J. Woll,Peter Reichardt,Axel Le Cesne,Sylvie Bonvalot,Alberto Azzarelli,Harald J. Hoekstra,Michael F. Leahy,Frits van Coevorden,Jaap Verweij,Pancras C.W. Hogendoorn,M. Ouali,Sandrine Marreaud,Vivien H.C. Bramwell,Peter Hohenberger,Peter Hohenberger +14 more
TL;DR: Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival and future studies should focus on patients with larger, grade III, and extremity sarcomas.
Journal ArticleDOI
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A.L.M. Eskens,Jaap Verweij +1 more
TL;DR: The most frequently occurring side- effects of both antibodies and tyrosine kinase inhibitors are described and some practical guidelines for treatment of the side-effects are given.
Journal ArticleDOI
Precision Oncology: An Overview
TL;DR: A systematic assessment of cancer genomic information and its accelerating clinical impact is presented and the remarkable technologic advances that make large-scale genomic data generation feasible in a clinical setting are reviewed.
Journal ArticleDOI
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
Sharyn D. Baker,Jaap Verweij,Eric K. Rowinsky,Ross C. Donehower,Jan H.M. Schellens,Louise B. Grochow,Alex Sparreboom +6 more
TL;DR: It is concluded that body surface area should not be used to determine starting doses of investigational agents in future phase I studies and alternate dosing strategies should be evaluated.